U.S. House introduces Microbicide Development Act of 2005

September 23, 2005

Washington, DC (September 23, 2005) -- The Alliance for Microbicide Development and the Global Campaign for Microbicides are pleased to announce the introduction of the "Microbicide Development Act of 2005." The bill was introduced in the U.S. House of Representatives by Representative Shays (R-CT) and Representative Schakowsky (D-IL).

"We need to dedicate more public health resources to developing microbicides quickly," said Representative Chris Shays of Connecticut. "In many settings, an HIV-infected woman has had only one partner: her husband. Microbicides are being developed with the goal that these products will allow women to protect themselves against the spread of disease and also allow them to conceive children. Current prevention options are not enough. If women and girls are to have a genuine opportunity to protect themselves, their best option is the rapid development of new HIV-prevention technologies like microbicides, which women can initiate."

"Microbicides could well be the first HIV prevention method that allows women to fight HIV-infection on their own. Even a partially effective microbicide could stop the infections of 2.5 million women over three years. This bi-partisan bill may be able to save a generation of women by developing this promising new preventive option," said Representative Jan Schakowsky of Illinois.

The bill seeks to establish a Microbicide Research and Development Unit at the National Institutes of Health and strengthen microbicide activity at USAID and the Centers for Disease Control. Named one of the "10 most promising biotechnologies for improving global health," microbicides are a class of products currently under development that women could apply topically to prevent transmission of HIV and other infections. Microbicides could come in a variety of forms, including gels, creams or rings that would release the drug slowly over days or weeks.

HIV infection rates among women have risen dramatically in recent years. Biologically, women are more than twice as susceptible to HIV as men. This vulnerability is exacerbated by widespread social inequality and poverty that make it difficult for women in many developing countries to insist upon condom use, abstinence or faithfulness with older or more powerful men. For women in many parts of the world, being poor and young are the most significant risk factors for acquiring HIV infection.

The feminization of the epidemic calls for a comprehensive approach to HIV/AIDS that includes prevention, treatment and care, as well as research into new prevention technologies such as microbicides. In addition, no existing HIV prevention method also allows conception. Some microbicides are being developed with the goal of allowing women to both conceive children and protect themselves from HIV.

The microbicide field has built an extraordinary amount of scientific momentum, with several first-generation candidates entering large-scale human effectiveness trials around the world. At the same time, new products, based upon recent advances in HIV treatment, are already well into safety trials. Given current scientific advancements an effective microbicide could be developed by the end of the decade, and once available, could well change the course of the AIDS epidemic.

Cosponsors of the Microbicide Development Act of 2005 at the time of introduction include: Rep Bean, Melissa L. [IL-8] -Rep Berman, Howard L. [CA-28]- Rep Brown, Sherrod [OH-13] - 9/21/2005 Rep Crowley, Joseph [NY-7] - Rep Davis, Danny K. [IL-7] - Rep Emanuel, Rahm [IL-5] - Rep Evans, Lane [IL-17] - Rep Grijalva, Raul M. [AZ-7] - Rep Gutierrez, Luis V. [IL-4] - Rep Honda, Michael M. [CA-15] - Rep Jackson, Jesse L., Jr. [IL-2] - Rep Kirk, Mark Steven [IL-10] - Rep Larson, John B. [CT-1] - Rep Leach, James A. [IA-2] - Rep Lee, Barbara [CA-9] - Rep McDermott, Jim [WA-7] - Rep McGovern, James P. [MA-3] - 9/21/2005 Rep McNulty, Michael R. [NY-21] - Rep Millender-McDonald, Juanita [CA-37] - Rep Miller, George [CA-7] - Rep Owens, Major R. [NY-11] - Rep Payne, Donald M. [NJ-10] - Rep Rush, Bobby L. [IL-1] - Rep Schakowsky, Janice D. [IL-9] - Rep Schwartz, Allyson Y. [PA-13] - Rep Stark, Fortney Pete [CA-13] - Rep Van Hollen, Chris [MD-8] - Rep Waxman, Henry A. [CA-30] - Rep Wexler, Robert [FL-19].
-end-
The Alliance for Microbicide Development is a global, multisectoral, multidisciplinary coalition founded to accelerate development of microbicides to prevent HIV/AIDS through advocacy, communication, convening, and addressing critical problems in practice and policy. http://www.microbicide.org

The Global Campaign for Microbicides is an international movement of activists, citizens and non profit organizations dedicated to accelerating access to new HIV prevention tools, especially for women. http://www.global-campaign.org

Global Campaign for Microbicides

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.